Dr. Lorraine Kalia’s research looks at testing different compounds in C. Elegans and how it can lead to a better understanding of Parkinson’s disease and new therapeutic targets. The best part: some of these compounds are already approved for use in humans. Through Dr. Kalia’s research we may be able to repurpose these compounds for the neurodegenerative condition.
Create your
podcast in
minutes
It is Free